Skip to main content
Lauren (Averett) Byers, MD, Oncology, Houston, TX

LaurenAverett(Averett)ByersMD

Oncology Houston, TX

MD Anderson Cancer Center

Dr. Byers is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Byers' full profile

Already have an account?

  • Office

    1515 Holcombe Blvd
    Houston, TX 77030
    Phone+1 713-792-6161

Summary

  • Dr. Lauren (Averett) Byers, MD is a Professor and Thoracic Section Chief in the Department of Thoracic/Head and Neck Medical Oncology at MD Anderson Cancer Center. Dr. Byers completed her B.A. degree in Molecular Biology at Princeton University in 1998, her M.D. degree at Baylor College of Medicine in 2003, and M.S. degree in Patient-Based Research at the University of Texas Graduate School of Biomedical Sciences in 2009. Following her Clinical Residency in Internal Medicine at Johns Hopkins Hospital, Dr. Byers joined MD Anderson Cancer Center in 2006 as a Clinical Fellow in Medical Oncology and later as an Advanced Scholar Fellow.

    As a physician-scientist, Dr. Byers’ research focuses on high-throughput molecular profiling to identify new therapeutic targets, predictive biomarkers, and mechanisms of resistance, especially in the area of Small Cell Lung Cancer (SCLC).

Education & Training

  • University of Texas Health Science Center at Houston
    University of Texas Health Science Center at HoustonFellowship, Medical Oncology, 2006 - 2009
  • Baylor College of Medicine
    Baylor College of MedicineClass of 2003

Certifications & Licensure

  • FL State Medical License
    FL State Medical License 2021 - Present
  • AZ State Medical License
    AZ State Medical License 2023 - 2026
  • TX State Medical License
    TX State Medical License 2006 - 2026
  • AL State Medical License
    AL State Medical License 2023 - 2025
  • MS State Medical License
    MS State Medical License 2023 - 2025
  • OK State Medical License
    OK State Medical License 2020 - 2025
  • TN State Medical License
    TN State Medical License 2023 - 2025
  • American Board of Internal Medicine Medical Oncology
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Differential Sensitivity Analysis for Resistant Malignancies (DISARM) Identifies Common Candidate Therapies Across Platinum-Resistant Cancers  
    Faye M Johnson, John V Heymach, Lauren Averett Byers, Clinical Cancer Research

Lectures

  • Phase 1 study of AMG 119, a chimeric antigen receptor (CAR) T cell therapy targeting DLL3, in patients with relapsed/refractory small cell lung cancer (SCLC). 
    ASCO Annual Meeting 2019 - Chicago, IL - 6/2/2019

Press Mentions

  • Durvalumab Wins FDA Approval in Limited-Stage SCLC
    Durvalumab Wins FDA Approval in Limited-Stage SCLCDecember 5th, 2024
  • How Are Targeted Therapies Used in Lung Cancer Treatment?
    How Are Targeted Therapies Used in Lung Cancer Treatment?July 30th, 2024
  • Limited-Stage SCLC Gets a New Standard of Care with Consolidation Durvalumab
    Limited-Stage SCLC Gets a New Standard of Care with Consolidation DurvalumabJune 3rd, 2024
  • Join now to see all